HAIFA, Israel, Oct. 27, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that Company executives will be participating in three upcoming conferences in Europe.
Pluristem recently reported its PLX-PAD cells have been selected for the European Medicines Agency’s Adaptive Pathways Project, which is designed to shorten the time it takes for innovative medicines to reach patients with serious conditions that lack adequate treatment option. The Company also recently expanded its Collaboration Research Agreement with the Berlin-Brandenburg Center for Regenerative Therapy at Charité - University Medicine Berlin.
BioEurope 2015
Date: November 2-5, 2015
Location: Munich, Germany
Hillit Mannor Shachar MD, MBA, Vice President Business Development, will participate in meetings with potential partners at BioEurope, which is Europe’s largest partnering conference serving pharma, biotech, and medical device companies.
ARM 3rd Annual Advanced Therapies Investor Day
Date: November 12, 2015
Location: London, England
Zami Aberman, Chairman and CEO, will be a speaker on the panel “Cell Therapy Commercialization”. The conference is hosted by the Alliance for Regenerative Medicine.
Berlin Dialogue
Date: November 17, 2015
Location: Berlin, Germany
Zami Aberman, Chairman and CEO, will participate in a dialogue session between the Berlin Senator of Economics, Technology and Research, representatives of academia and companies from the field of life sciences on the topic of “Furthering the Innovative Co-Operation Models between Industry and Academia on the Way to a Strategically Laid Out Long-Term Partnership in the Field of Life Sciences and Medicine”.
About Pluristem Therapeutics
Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company has reported robust clinical trial data in multiple indications for its patented PLX (PLacental eXpanded) cells. The cells release a cocktail of therapeutic proteins in response to inflammation, ischemia, hematological disorders, and radiation damage. PLX cell products are grown using the Company's proprietary three-dimensional expansion technology. They are off-the-shelf, requiring no tissue matching prior to administration. Pluristem has a strong intellectual property position; Company-owned, GMP-certified manufacturing and research facilities; strategic relationships with major research institutions; and a seasoned management team.
Pluristem Therapeutics Inc.
Karine Kleinhaus, MD, MPH
Divisional VP, North America
1-914-512-4109
karinek@pluristem.com
